Leading diagnostics chains unveil Eastern India’s largest & first state-of-the-art genomics lab with a grand inauguration event
DSIJ Intelligence-1Categories: Mindshare, Trending
The company has a market cap of Rs 1,682 crore with a PE of 54x, an ROE of 16 per cent and an ROCE of 18 per cent. The
Suraksha Diagnostic Limited has launched Eastern India's largest and first state-of-the-art genomics lab in Kolkata. Graced by Prof. Sukumar Mukherjee, the inauguration marks a significant step in addressing the urgent need for accessible genomic diagnostics in West Bengal, aligning with the resurgence in medical education and services in the state. This initiative aims to enhance preventive care by enabling early and accurate risk detection and facilitating better treatment planning.
The company has made a substantial investment of ₹22 crores in establishing this cutting-edge facility, with an additional ₹46 crore planned over the next two years to develop one of Asia's most advanced genomics laboratories. This strategic move by Suraksha Diagnostic positions West Bengal and the broader Eastern and North-Eastern regions of India at the forefront of precision diagnostics, tapping into a global genetic testing market projected to reach USD 186.64 billion by 2035.
Equipped with advanced technologies such as Cytogenetics, Microarray Technology, Sanger Sequencing and multiple Next-Generation Sequencers (NGS), the lab offers a full spectrum of advanced genetic testing for predictive, preventive and personalised care. This includes the detection of chromosomal abnormalities for informed parental decisions, pioneering onco-genomics with hereditary cancer testing panels for early detection and personalised cancer treatment and detailed genetic analysis through various sequencing methods, making Suraksha Diagnostic a leader in personalised oncology diagnostics in Eastern India.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Established in 1992, Suraksha Diagnostic has grown into a prominent diagnostics provider, offering a comprehensive range of over 2,300 tests across pathology, radiology and medical consultancy services. The company operates a central reference laboratory, eight satellite laboratories, 59 diagnostic centres and 166 sample collection centres across West Bengal, Bihar, Assam and Meghalaya. Suraksha's commitment to technological advancement is evident in its adoption of AI-enabled smart labs and digital platforms, streamlining operations and enhancing patient care.
In December 2024, Suraksha Diagnostic completed its Initial Public Offering (IPO), raising Rs 846.25 crore. The IPO was subscribed 1.27 times, reflecting strong investor confidence in the company's growth trajectory. The company has a market cap of Rs 1,682 crore with a PE of 54x, an ROE of 16 per cent and an ROCE of 18 per cent. The stock is up by 39.4 per cent from its 52-week low of Rs 233.15 per share.
Disclaimer: The article is for informational purposes only and not investment advice.